Literature DB >> 30148169

Prospects of Noncoding RNAs in Hepatocellular Carcinoma.

Huaixiang Zhou1,2, Qiuran Xu1,2, Chao Ni1,3, Song Ye4, Xiaowu Xu2, Xiaoge Hu1,2, Jiahong Jiang5, Yeting Hong6, Dongsheng Huang1, Liu Yang1,2.   

Abstract

Hepatocellular carcinoma (HCC) is a global health problem and one of the most common malignant tumors. Recent studies have shown that noncoding RNAs (ncRNAs) contribute to the pathogenesis of hepatocellular carcinoma (HCC). These RNAs may be involved in a variety of pathological processes such as cell proliferation, apoptosis, angiogenesis, invasion, and metastasis. In addition, abnormal expression of ncRNAs in HCC may provide potential prognostic or diagnostic biomarkers. This review provides an overview of the role and potential applications of ncRNAs, miRNAs, lncRNAs, circRNAs, and snoRNAs in liver cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30148169      PMCID: PMC6083484          DOI: 10.1155/2018/6579436

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and a global health problem [1]. Like many other cancers, HCC is characterized by the involvement of multiple gene networks and the imbalance of signaling pathways [2, 3]. These genetic dysregulations involve protein-coding genes and noncoding RNA (ncRNA) genes [4]. Although the former has been the focus of research, the latter has only recently been recognized as playing a role in the pathological processes implicated in HCC [5]. Interestingly, the vast majority of the human genome is transcribed into ncRNA, while less than 2% of the genome directly encodes for proteins [6]. Noncoding RNA is a functional RNA that is not translated into protein [7]. NcRNAs include ribosomal RNA (rRNA), transfer RNA (tRNA), and small nuclear ribonucleic acids (snRNA) that process pre-mRNA, small nucleolar RNA (snoRNA), piwi-interacting RNA (piRNA), microRNA (miRNA), long noncoding RNA (lncRNA), etc. [7]. The common characteristic of these RNA is their ability to exercise their biological functions at the level [8]. Prior work has generally focused on protein-coding genes, with little focus on ncRNA function, often dismissed as nothing more than transcriptional noise [9]. However, recent studies have discovered that ncRNAs play an important role in many biological processes. Research in the field of ncRNA has shown an explosive growth in recent years since their functional role has been recognized [10-12]. With the development of high-throughput sequencing technology, many ncRNAs have been characterized as functional molecules that play an important role in various biological processes and pathological states [13-15]. In the field of hepatocellular carcinoma, some key ncRNAs have been identified as participants in the pathophysiology of the disease [16, 17]. Thousands of universally transcribed ncRNAs have been identified, and these transcripts greatly outnumber those of protein-coding mRNAs [18]. In addition, some ncRNAs show significant evolutionary conservation, indirectly supporting their functional roles [19, 20]. For example, miRNA and lncRNAs regulate different biological and pathological processes, such as tumor occurrence [21-24].

2. Abnormal Expression miRNAs in HCCs and Serum of Patients with Hepatocellular Carcinoma

MicroRNA (miRNA) is a type of 20-24nt long biologically functional, small molecule that is highly conserved and provides negative regulation [25]. Since their discovery in 1993 in Caenorhabditis elegans, their important roles continue to be described [26, 27]. Their main functions are on the transcription of regulatory proteins encoded by gene expression [28-30]. Liver cancer is both common and lethal, mainly due to ineffective treatment options [31, 32]. MiRNAs regulate protein synthesis and could either be therapeutic agents or targets for intervention [33-35]. It is clear that miRNA plays a role in proliferation, persistence, invasion, metastasis, and prognostic indicators of hepatocellular carcinoma [36-39]. In liver cancer tissue, there are many abnormally expressed miRNAs, such as miR-224, miR-221, and miR-21 that influence hepatocellular carcinoma [40-42]. miR-224 has been shown to target HOXD10 RNA and enhance both PAK4-mediated phosphorylation and MMP-9 to promote the invasion and metastasis of cancer cells [43]. MiR-224 can inhibit SMAD4 expression and promote cell proliferation [44]. Also, miR-224 can target ppp2r1b leading to excessive activation of the AKT signaling pathway, increasing the risk of liver cancer [45]. MiR-221 can target cell cycle kinase inhibitory proteins p27 and p57, thereby promoting the progression of HCC cell cycle [46, 47]. At the same time, miR-221 can interfere with the mTOR signaling pathway by inhibiting another target DDIT4, thus promoting tumor development [48]. MiR-221 expression levels can be raised by HCV infection, a process that relies on the activation of NF-κB signaling [49]. MiR-221 can also target SOCS1 and SOCS3, enhancing the activation of the downstream interferon signaling pathway, thus enhancing the effectiveness of interferon against HCV [50]. In HCC cells, miR-21 can target MAP2K3 and promote the proliferation of cancer cells [51]. In parallel, miR-21 can inhibit PDCD4, thus activating the expression of downstream c-Jun, MMP-2, and MMP-9. Furthermore, AP-1 can modulate the transcription of miR-21 in a positive feedback loop, further increasing the risk of liver cancer invasion and metastasis [52]. The role of abnormally expressed miRNAs in HCCs and in the serum of HCC patients is listed in Table 1. Clinical data has shown that miR-21 expression in tumors of HCC patients is relatively high [85]. The response to postoperative IFN-Α/5-FU combined treatment is poor [86], suggesting that miR-21 may be a potential molecular marker for prognostic judgment and treatment of HCC. There are many abnormally expressed miRNAs in the serum of HCC patients. Among them, miR-16, let-7f, miR-21, miR-139, miR-101, miR-122, and miR-1 show reduced expression [87-90]. High expression of mir-17-5p may be indicative of HBV (Hepatitis B virus) and the recurrence of HCC [90]. In HCV-infected sera from HCC patients, the specific low expression of mir-30c-5p, mir-223-3p, mir-302c-5p, and mir-17-5p, as well as the specific high expression of miR-221, also suggest potential biomarkers indicating the recurrence of HCC [91, 92].
Table 1

The function of abnormal expression miRNAs in HCC and in the serum of HCC patients.

miRNAsTarget geneFunctionReferences
miR-224HOXD10Promoting the invasion and metastasis of cancer cells[43]
miR-224SMAD4Promoting cell proliferation[44]
miR-224ppp2r1bIncreasing the risk of liver cancer[45]
miR-221p27 and p57Promoting the progression of hepatocellular carcinoma cell cycle[46, 47]
miR-221DDIT4Promoting tumor development[48]
miR-221SOCS1 and SOCS3Enhancing the effectiveness of interferon against HCV[50]
miR-21map2k3Promoting the proliferation of cancer cells[51]
miR-21PDCD4Increased the risk of liver cancer invasion and metastasis[52]

3. Roles of lncRNAs in HCC

Ten of thousands of lncRNAs are transcribed in humans [93]. Importantly, detecting their targets is challenging in contrast to miRNA [94]. Indeed, lncRNAs often need to form complex secondary and tertiary structures to predict targets [95]. With the development of large scale parallel sequencing technology, lncRNA has been shown to play an important role in the development of human HCC [96]. So far, many HCC-related lncRNA disorders, such as HULC, HOTAIR, MALAT1, and H19, have been used as predictive biomarkers for human disease diagnosis or prognosis [97, 98]. Furthermore, there is strong evidence that lncRNAs are associated with HCC via many signaling pathways. MyD88 levels were found to be elevated in multiple solid tumors, especially HCC [99]. Many ncRNAs, through a variety of mechanisms, regulate the location of binding sites of protein-coded genes. The abnormal increase in the expression of a new long noncoding Myd88 RNA (lnc-Myd88) is associated with HCC [66]. Chip analysis showed that lnc-Myd88 could increase Myd88 expression by enhancing the acetylation of H3K27 at the Myd88 gene promoter region, leading to the activation of NF-κB and PI3K/AKT signaling pathways [66]. Thus, lnc-Myd88 may be a new diagnostic and therapeutic target for HCC. Various examples of lncRNAs regulating signaling pathways in HCC are listed in Table 2. Hence, targeting these lncRNAs in combination with other therapeutic agents could have therapeutic potential for HCC.
Table 2

Signaling pathways in HCC regulated by lncRNAs.

lncRNAsPathwaysFunctionsReferences
URHCERK/MAPK pathwayRegulates cell proliferation and apoptosis[53]
HULCRXRA pathwayModulates abnormal lipid metabolism[54]
LINC00152mTOR pathwayPromotes proliferation in HCC[55]
LINC01225EGFR-dependent pathwayPromotes occurrence and metastasis of HCC[56]
CCHE1ERK/MAPK pathwayPromotes carcinogenesis of HCC[57]
linc-cdh4-2R-cadherin pathwayInhibits the migration and invasion of HCC cells[58]
lncARSRPTEN-PI3K/Akt Pathway.Promotes doxorubicin resistance in HCC[59]
TSLNC8Interleukin-6/STAT3 pathwayA tumor suppressor[60]
PDIA3P1p53 pathwayPromotes cell proliferation, migration and invasion, and suppresses apoptosis[61]
lncRNA00673Notch pathwayPromotes of proliferation and metastasis of HCC[62]
Igf2asERK/MAPK pathwayControls hepatocellular carcinoma progression[63]
CCALWnt/β-catenin pathwayPromotes HCC progression[64]
LncDQEMT PathwayPromotes HCC progression[65]
lnc-Myd88NF-κB and PI3K/AKT pathwaysPromotes HCC progression[66]
In addition, a new concept suggests that lncRNAs could be used as a protein scaffold close together to form ribose nuclear proteins [100]. However, only a few scaffolding lncRNAs have been identified and the broad extent of this function is unknown. LncRNAs participate in a variety of biological processes and play an important role in various human diseases, including fibrosis diseases, liver diseases, and rare human diseases [101-104]. With the rise of RNA sequencing (RNA-Seq) technology, the number of lncRNAs identified has increased rapidly [105]. However, most lncRNAs have not been well annotated, and their regulatory mechanisms remain elusive. Furthermore, many lncRNAs are not evolutionarily conserved [106]. Therefore, it is vital to study the key function of the conserved lncRNAs.

4. circRNA and HCC

In addition to miRNA and lncRNA, other ncRNAs also influence the development of HCC [67, 107]. Circular RNAs (circRNAs) were discovered in mouse testes in 1993 [108] and represent another class of endogenous, noncoding RNA. In addition to being a biomarker for HCC, circRNA has recently been found to be an important gene expression and pathological network regulatory factor [109-111]. The interactions of hsa_circ_0005075-targeted miRNA genes, including miR-23b-5p, miR-93-3p, miR-581, miR-23a-5p, and their corresponding mRNA, have been studied [70]. One circRNA, Cdr1as, inhibits and absorbs microRNA-7 (miR-7), a suppressor of HCC [69]. CircMTO1 (hsa_circRNA_0007874/ hsa_circRNA_ 104135) suppresses HCC progression by absorbing oncogenic miR-9, thus promoting p21 expression [68]. Recently, circrna_100338 was identified as a biomarker for HCC diagnosis and target for HCC therapeutics [67]. circRNAs function as microRNA sponges by targeting related genes shown in Figure 1 (modified from [108]) and Table 3. In addition, circ_0067934 directly inhibits miR-1324 that targets the 3′-UTR of FZD5 mRNA. Subsequently, the Wnt/β-catenin signaling pathway becomes downregulated in HCC, which enhances the proliferation, migration, and invasion of HCC [112].
Figure 1

circRNAs function as microRNA sponges by targeting related genes.

Table 3

circRNAs function as microRNA sponges in HCC.

circRNAmicroRNA spongesCellsReferences
circRNA_10033miR-141-3pHCC and MHCC97H[67]
circMTO1miR-9HCC[68]
CDR1asmiR-7HCC cells, SMMC-7221, Hep3B, QGY-7703, and HepG2[69]
hsa_circ_0005075miR-23b-5p, miR-93-3p, miR-581, miR-23a-5pHCC cells, HepG2, and SNU449[70]
hsa_circ_0001649miR-1297HCC cells, HepG2, and SMMC7721[71]

5. snoRNA and Their Host Genes in HCC

Small nucleolar RNAs (snoRNAs) are a novel molecular species that may have significant influence on the development and progression of HCC [78]. The expression of snord113-1 in HCC is significantly downregulated [72]. The reduction of snord113-1 in HCC was clearly associated with decreasing patient. In essence, snord113-1 functionally inhibits the growth of HCC cells [72]. Small nucleolar RNA host gene 20 (SNHG20) expression in sk-hep-1 cells significantly inhibited cell proliferation, migration, and invasion. This suggests that SNHG20 could be used as an independent prognostic predictor for HCC patients [74]. The potential roles of snoRNA or their host genes in liver cancer are listed in Table 4.
Table 4

Potential role of snoRNA or their host genes in liver cancer.

SnoRNA/ their host genesPotential role in liver cancerCellsReferences
SNORD113-1A tumor suppressor role in HCC and a potential diagnostic and therapeutic target for HCC.HepG2 and Huh7[72]
SNHG3Associated with malignant status and poor prognosis in HCC patients.HCC[73]
SNHG20Up-regulated in patients with HCC, served as an independent prognostic predictor for HCC patients.HCC and SK-Hep-1[74, 75]
SNHG1A prognostic biomarker and therapeutic target for HCC.HCC and HepG2[76, 77]
SNORD78Associated with aggressive phenotype and poor prognosis of HCCSK-Hep-1[78]
SNHG6Impacts HCC tumorigenesis by binding to up-frameshift protein 1 and regulating Smad7 expression.HCC and L02[79]
SNORD126A therapeutic targetHepG2, LS174T and Huh7[80]
SNHG12A biomarker and a potential therapeutic target for HCC.HCC[81]
ACA11A promising prognostic biomarker and therapeutic target for patients with HCC.HCCLM9 and SK-Hep1[82]
snoRA47A valuable biomarker and a potential therapeutic target for HCC.HCC[83]
SNORD76A promising prognostic biomarker in patients with HCC.SK-Hep1 and Huh7[84]

6. Conclusion

This review provides an overall view of ncRNA in hepatocellular carcinoma (HCC). In addition to the recent focus of research towards lncRNA and miRNA, other ncRNAs, including circRNA and snoRNA also influence liver cancer. Although the first miRNA was identified 20 years ago, other ncRNAs including lncRNAs, snoRNA, siRNA, and piRNAs were gradually discovered and proved to be important in the pathogenesis of cancer [113]. To fully grasp the complete picture of the role of ncRNAs in the pathogenesis of HCC, it is paramount to explore the regulatory networks including circRNA-mRNA, miRNA-lncRNA, lncRNA/snoRNA-piRNA, and other networks that have not been found. To fully understand the biological functions of ncRNAs, we must ascertain the functions of all the proteins and ncRNAs of each cell type and the interactions among them. This full understanding is still a long way off, far more difficult than the genome project.
  112 in total

1.  TYRP1 mRNA goes fishing for miRNAs in melanoma.

Authors:  Maria S Soengas; Eva Hernando
Journal:  Nat Cell Biol       Date:  2017-10-31       Impact factor: 28.824

2.  Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway.

Authors:  Yang Kong; Lufei Zhang; Yu Huang; Tianyu He; Linshi Zhang; Xinyi Zhao; Xiaohu Zhou; Dongkai Zhou; Yingcai Yan; Jiarong Zhou; Haiyang Xie; Lin Zhou; Shusen Zheng; Weilin Wang
Journal:  Cancer Lett       Date:  2017-08-18       Impact factor: 8.679

Review 3.  Progress and Prospects of Long Noncoding RNAs (lncRNAs) in Hepatocellular Carcinoma.

Authors:  Chen Li; Jing Chen; Kai Zhang; Bing Feng; Rui Wang; Longbang Chen
Journal:  Cell Physiol Biochem       Date:  2015-05-11

4.  Small nucleolar RNA 47 promotes tumorigenesis by regulating EMT markers in hepatocellular carcinoma.

Authors:  Guangcai Li; Yuan He; Xiaoqing Liu; Zhen Zheng; Ming Zhang; Faxiang Qin; Xiong Lan
Journal:  Minerva Med       Date:  2017-05-02       Impact factor: 4.806

5.  miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.

Authors:  Qin Zhu; Zhiming Wang; Yu Hu; Jindong Li; Xinying Li; Ledu Zhou; Yun Huang
Journal:  Oncol Rep       Date:  2012-02-09       Impact factor: 3.906

6.  MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3.

Authors:  Guangxian Xu; Yilin Zhang; Jun Wei; Wei Jia; Zhaohui Ge; Zhaobo Zhang; Xiaoming Liu
Journal:  BMC Cancer       Date:  2013-10-10       Impact factor: 4.430

7.  MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.

Authors:  Daniel Yee; Kunal M Shah; Mark C Coles; Tyson V Sharp; Dimitris Lagos
Journal:  J Biol Chem       Date:  2017-10-24       Impact factor: 5.157

Review 8.  Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma.

Authors:  Ioannis A Ziogas; Georgios Tsoulfas
Journal:  World J Gastrointest Surg       Date:  2017-12-27

9.  Suppression of endothelial cell migration by tumor associated macrophage-derived exosomes is reversed by epithelial ovarian cancer exosomal lncRNA.

Authors:  Quanfeng Wu; Xiaoli Wu; Xiang Ying; Qinyi Zhu; Xinjing Wang; Lu Jiang; Xin Chen; Yueqian Wu; Xipeng Wang
Journal:  Cancer Cell Int       Date:  2017-06-06       Impact factor: 5.722

Review 10.  Epigenetic reprogramming in liver fibrosis and cancer.

Authors:  Caroline L Wilson; Derek A Mann; Lee A Borthwick
Journal:  Adv Drug Deliv Rev       Date:  2017-10-25       Impact factor: 15.470

View more
  5 in total

1.  Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.

Authors:  Ling Liu; Xin Yang; Nian-Feng Li; Ling Lin; Hui Luo
Journal:  Cell Cycle       Date:  2019-09-16       Impact factor: 4.534

2.  MALAT1 functions as a competing endogenous RNA to regulate SMAD5 expression by acting as a sponge for miR-142-3p in hepatocellular carcinoma.

Authors:  Qiangfeng Yu; Leyang Xiang; Zhanjun Chen; Xincheng Liu; Huohui Ou; Jianyin Zhou; Dinghua Yang
Journal:  Cell Biosci       Date:  2019-05-10       Impact factor: 7.133

Review 3.  Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.

Authors:  Jingxian Duan; Yuling Wu; Jikui Liu; Jiajia Zhang; Zhichao Fu; Tieshan Feng; Ming Liu; Jie Han; Zhicheng Li; Shifu Chen
Journal:  J Hepatocell Carcinoma       Date:  2019-10-18

Review 4.  Circulating Non-Coding RNAs as Potential Diagnostic Biomarkers in Hepatocellular Carcinoma.

Authors:  Tingsong Chen
Journal:  J Hepatocell Carcinoma       Date:  2022-09-15

5.  Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.

Authors:  Hui He; Yawei Wang; Peng Ye; Dehui Yi; Ying Cheng; Haibo Tang; Zhi Zhu; Xun Wang; Shi Jin
Journal:  J Exp Clin Cancer Res       Date:  2020-08-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.